Your AI-Trained Oncology Knowledge Connection!
Aditya Shreenivas, M.D., M.S. is an assistant clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope.
Dr Shreenivas on the FDA Approval of Penpulimab Plus Chemo for Frontline Non-Keratinizing Nasopharyngeal Carcinoma
Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab plus chemotherapy for the frontline treatment of non-keratinizing nasopharyngeal carcinoma.
Read More
Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers
Aditya Shreenivas, MD, MS, discusses the association between MUC1 and Claudin 18 in GI cancers.
Keeping Ahead of Oncology Advances Requires Vigilance
Aditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer
BGB-16673 Displays a High ORR and Tolerability in Waldenström Macroglobulinemia
GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting